Nuedexta (dextromethorphan HBr and quinidine sulfate) vs Pheburane (sodium phenylbutyrate)

Nuedexta is a combination medication primarily used for the treatment of pseudobulbar affect (PBA), a condition characterized by sudden, uncontrollable episodes of crying or laughing, whereas Pheburane (sodium phenylbutyrate) is used for the management of urea cycle disorders, which are genetic conditions that lead to high ammonia levels in the blood. The active components in Nuedexta work by affecting the signaling in the central nervous system to help control the emotional responses associated with PBA, while Pheburane serves as a nitrogen-scavenging agent to help rid the body of excess ammonia. Therefore, the choice between Nuedexta and Pheburane would be based on the specific condition being treated: PBA for Nuedexta and urea cycle disorders for Pheburane, and they are not interchangeable.

Difference between Nuedexta and Pheburane

Metric	Nuedexta (dextromethorphan HBr and quinidine sulfate)	Pheburane (sodium phenylbutyrate)
Generic name	Dextromethorphan hydrobromide and quinidine sulfate	Sodium phenylbutyrate
Indications	Treatment of pseudobulbar affect (PBA)	Treatment of urea cycle disorders
Mechanism of action	Dextromethorphan acts on the central nervous system to modulate the excitability of neurons, while quinidine increases its bioavailability by inhibiting its metabolism.	Converts to phenylacetate in the body, which then conjugates with glutamine to form phenylacetylglutamine, thereby reducing ammonia levels.
Brand names	Nuedexta	Pheburane, Buphenyl
Administrative route	Oral	Oral
Side effects	Dizziness, nausea, vomiting, cough, peripheral edema, urinary tract infections, flu symptoms	Bad taste in the mouth, body odor, headache, nausea, vomiting, lack of appetite, rash
Contraindications	Patients taking MAOIs, patients with a history of heart rhythm disorders	Patients with hypersensitivity to phenylbutyrate or its derivatives
Drug class	Central nervous system agent	Urea cycle disorder agent
Manufacturer	Avanir Pharmaceuticals	Lucane Pharma

Efficacy

Nuedexta and Amyotrophic Lateral Sclerosis (ALS)

Nuedexta is a combination medication consisting of dextromethorphan HBr and quinidine sulfate and is primarily approved by the FDA for the treatment of pseudobulbar affect (PBA). PBA is a condition characterized by sudden and uncontrollable laughing or crying, and it is commonly associated with neurological disorders such as ALS. The efficacy of Nuedexta in treating PBA in ALS patients has been demonstrated in clinical trials. These trials have shown that Nuedexta can significantly reduce the frequency and severity of PBA episodes in patients with ALS, thereby improving their emotional lability and quality of life.

While Nuedexta is not specifically approved for the treatment of ALS itself, its impact on PBA, a symptom experienced by many ALS patients, is relevant. ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to loss of muscle control. The efficacy of Nuedexta in altering the progression of ALS or improving motor function has not been established, and its use in this context remains off-label.

Pheburane and Amyotrophic Lateral Sclerosis (ALS)

Pheburane (sodium phenylbutyrate) is a medication that is used for the treatment of urea cycle disorders, which are genetic disorders that lead to an accumulation of ammonia in the blood. Its efficacy in this indication is well-documented. However, its use in Amyotrophic Lateral Sclerosis (ALS) is considered off-label and is based on the hypothesis that sodium phenylbutyrate may have neuroprotective effects due to its role in promoting the excretion of nitrogen and reducing ammonia toxicity.

Research on the efficacy of Pheburane for ALS is limited and primarily experimental. Some studies suggest that sodium phenylbutyrate may have a potential role in modulating stress responses within the nervous system, which could theoretically be beneficial in neurodegenerative diseases like ALS. However, there is a lack of large-scale, definitive clinical trials that confirm the efficacy of Pheburane in treating ALS. Therefore, while there may be a scientific rationale for its use, the evidence to support the efficacy of Pheburane specifically for ALS is not conclusive and should be approached with caution.

Regulatory Agency Approvals

Nuedexta

Food and Drug Administration (FDA), USA

Pheburane

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Nuedexta or Pheburane today

If Nuedexta or Pheburane are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Nuedexta

Buy Pheburane

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: